Oryon Cell Therapies emerged from stealth with Phase Ib/IIa data on an autologous neuron‑replacement therapy for Parkinson’s disease and announced new funding and leadership moves. The company presented early human data at the AD/PD conference and disclosed a $21 million financing tranche to extend development. In a separate filing, Ron Cohen, former Acorda CEO, was named Oryon’s chief executive, joining as the startup aims to scale its autologous stem‑cell approach derived from work at McLean Hospital and Harvard Medical School. Oryon said it will continue clinical development while expanding management and funding to support next‑stage studies.